•   
  •   
W

World WHO approves emergency use of China’s Sinopharm COVID vaccine

21:31  07 may  2021
21:31  07 may  2021 Source:   aljazeera.com

Australians are getting vaccinated in China. But will their jabs be recognised here or will they have to get a second round of shots?

  Australians are getting vaccinated in China. But will their jabs be recognised here or will they have to get a second round of shots? Some Australians are getting their COVID-19 vaccine in China. But as Australia hasn't approved the Sinopharm or Sinovac jabs, there are lingering questions over whether they'll be seen as vaccinated or not.Instead, she will be immunised with China's Sinovac vaccine.

The World Health Organization has approved the emergency use of a COVID-19 vaccine manufactured by China’s Sinopharm.

a hand holding a remote control: Sinopharm has not published its late-stage test results in scientific journals [File: Zhang Yuwei/Xinhua via AP] © Sinopharm has not published its late-stage test results in scientific journals [File: Zhang Yuwei/Xi... Sinopharm has not published its late-stage test results in scientific journals [File: Zhang Yuwei/Xinhua via AP]

Friday’s decision by a WHO technical advisory group, a first for a Chinese vaccine, opens the possibility that Sinopharm’s offering could be included in the United Nations-backed COVAX programme in coming weeks or months, and distributed through United Nations children’s agency UNICEF and WHO’s Americas regional office.

Pfizer COVID Vaccine Likely Will Need Third Booster Shot, BioNTech CEO Says

  Pfizer COVID Vaccine Likely Will Need Third Booster Shot, BioNTech CEO Says Ugur Sahin, BioNTech's chief executive, said Wednesday that the vaccine his company created with Pfizer will likely require a third booster shot due to data showing a weaker immune response over time in people who received the vaccine.According to studies, the efficacy of the BioNTech-Pfizer vaccine drops from 95% to 91% after six months. Sahin said people who receive two doses of the vaccine should get the third dose nine to 12 months after the first shot.

Aside from efficacy numbers, the Chinese manufacturer has released very little public data about its two vaccines – one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.

The Beijing shot is one the WHO advisory group considered for the emergency use listing.

“This afternoon, WHO gave emergency use listing to sign off on Beijing’s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality,” WHO Director-General Tedros Adhahom Ghebreyesus said.

The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorisation from the UN health agency.

China Is a Paper Dragon

  China Is a Paper Dragon U.S. policy makers should look to the future with a little more confidence and a lot more trust in trade, markets, and the superior potential of a free people.As Biden said to the nation from the well of the House of Representatives, the authoritarian President Xi Jinping is “deadly earnest” about China “becoming the most significant, consequential nation in the world. He and others—autocrats—think that democracy can’t compete in the 21st century with autocracies.

“This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine,” Tedros said at a Geneva news conference.

‘Very confident’

Previously, a separate group advising WHO on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59.

The group said it had a “low level of confidence” in the vaccine’s efficacy for people 60 and over.

Its members said they had “very low confidence” in the available data about serious side effects in that age group.

Sinopharm has not published its late-stage test results in scientific journals, so the WHO requested a breakdown of its data, which come mostly from the United Arab Emirates.

A summary posted online by WHO suggests the vaccine is about 78 percent effective, with the caveat that all but a few hundred of the study volunteers were younger than 60.

Gavi, the Vaccine Alliance, which co-runs COVAX, welcomed the announcement.

“This means the world has yet another safe and effective tool in the fight against this pandemic,” the alliance said.

The public-private partnership said it was in discussions with several manufacturers, including Sinopharm, “to expand and diversify the portfolio further and secure access to additional doses” for countries in the COVAX programme.

COVAX aims to send vaccines for free to 92 lower-income countries and to help another 99 countries and territories procure them.

It was not immediately clear when the Chinese vaccine might be made available to the COVAX portfolio.

Beers, doughnuts, and discounts: The growing list of vaccine freebies .
Half of American adults have received one vaccine dose. Could incentives close the gap?Major corporations began announcing initiatives that “strongly encouraged” employee vaccination as early as February, with some offering extra pay and bonuses. As of late, however, such messaging has been geared toward the general public. In May, the White House announced a nationwide partnership with Uber and Lyft to offer free rides to and from vaccination sites from May 24 until July 4; it will also work with national grocery chains, retailers, and sports leagues to offer discounts and promotions for those who have been vaccinated.

usr: 1
This is interesting!